Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter Randomized Double-Blind Placebo and Active Comparator Controlled Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of MBX-8025 in Moderately Obese Hyperlipidemic Patients With/Out Concomitant Atorvastatin"
Brief Summary: A Multicenter Randomized, Double-Blind, Placebo-Controlled Study to evaluate the efficacy, safety and tolerability of MBX-8025, a novel PPAR-d agonist to treat hyperlipidemia, insulin resistance and obesity in overweight, hyperlipidemic patients, both as monotherapy and in combination with Atorvastatin

Total participation for each patient is approximately 16-17 weeks, which may include up to a 2 week screening period, 5 week run-in period, 8 week treatment period, and 2 week follow-up. During the run-in period patients taking statins, statin combination or Zetia will undergo a 'washout'. All patients will be instructed to follow a weight-maintenance diet (i.e., their same diet prior to entering the study). They will be asked to defer initiating any weight loss diets or meaningful changes in their activity level until after they have completed the study. Once randomized into the double blind study, patients will visit the clinic every two weeks thereafter until the end of the study. At the end of the 8-week treatment phase, the double-blind study medication will be discontinued. Patients will attend a follow up visit two weeks after their final dose for safety evaluation.


Options:
A: Arm Label: Pitavastatin; Type: EXPERIMENTAL; Interventions: Drug: Pitavastatin | Arm Label: Atorvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Intervention Type: DRUG; Name: Pitavastatin; Assigned to Arm(s): Pitavastatin | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Atorvastatin
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Simvastatin | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): 3
C: Arm Label: Placebo/Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: MBX-8025 50 mg/Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: MBX-8025 | Arm Label: MBX-8025 100 mg/Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: MBX-8025 | Arm Label: Placebo/Atorvastatin 20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: Atorvastatin | Arm Label: MBX-8025 50 mg/Atorvastatin 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Atorvastatin, Drug: MBX-8025 | Arm Label: MBX-8025 100 mg/Atorvastatin 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Atorvastatin, Drug: MBX-8025 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): MBX-8025 100 mg/Placebo, MBX-8025 50 mg/Placebo, Placebo/Atorvastatin 20 mg, Placebo/Placebo | Intervention Type: DRUG; Name: MBX-8025; Assigned to Arm(s): MBX-8025 50 mg/Placebo | Intervention Type: DRUG; Name: MBX-8025; Assigned to Arm(s): MBX-8025 100 mg/Placebo | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): MBX-8025 100 mg/Atorvastatin 20 mg, MBX-8025 50 mg/Atorvastatin 20 mg, Placebo/Atorvastatin 20 mg | Intervention Type: DRUG; Name: MBX-8025; Assigned to Arm(s): MBX-8025 50 mg/Atorvastatin 20 mg | Intervention Type: DRUG; Name: MBX-8025; Assigned to Arm(s): MBX-8025 100 mg/Atorvastatin 20 mg
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: Atorvastatin | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Atorvastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C